Angela Drew, PhD, has been a regulatory strategist since 2011. During this time, she has prepared regulatory submissions, conducted FDA meetings to obtain feedback on development programs, and advised clients on developing products for submission via the 505(b)(2) regulatory pathway. Prior to joining the pharmaceutical industry as part of the Premier team, Angela held academic appointments at the University of Cincinnati and Melbourne University investigating the interactions between inflammation, coagulation, and cancer metastasis.